To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes

Novartis

Status and phase

Completed

Phase 3

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: Vildagliptin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00368134

CLAF237A1301

Details and patient eligibility

About

This study is designed to evaluate the efficacy, safety and tolerability of vildagliptin compared to voglibose in patients with type 2 diabetes. Please note this study is not being conducted in the United States.

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis as Type 2 Diabetes
Patients who have been placed on dietary therapy/exercise therapy, without achievement of glycemic control
Outpatients

Exclusion criteria

Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
Significant heart diseases
Significant diabetic complications

Other protocol-defined inclusion/exclusion criteria may apply